Uso de factor VII en el control de sangrados perioperatorios: Evidencias actuales

Recombinant activated factor VII (rFVIIa) is a new haemostatic drug, originally used for the treatment of patients with hemophilia A and B. At the present time it is used for other bleeding conditions such as the perioperative period. When used prophylactically there is a reduction in the number of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	López B,Rodrigo, Aeschlimann D,Nicolás, Carvajal F,Claudia, Lema F,Guillermo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2009
Materias:	Blood componenit transfusion Factor VII a Postoperative hemorrhage
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000600016
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872009000600016
record_format	dspace
spelling	oai:scielo:S0034-988720090006000162009-09-04Uso de factor VII en el control de sangrados perioperatorios: Evidencias actualesLópez B,RodrigoAeschlimann D,NicolásCarvajal F,ClaudiaLema F,Guillermo Blood componenit transfusion Factor VII a Postoperative hemorrhage Recombinant activated factor VII (rFVIIa) is a new haemostatic drug, originally used for the treatment of patients with hemophilia A and B. At the present time it is used for other bleeding conditions such as the perioperative period. When used prophylactically there is a reduction in the number of bleeding episodes but no changes in the need for blood transfusion or other blood products. The adverse effects are arterial or venous thromboembolic events that are mostly related to the severity of the underlying disease of the patient and the concurrent administration of other haemostatic agents, rather than the use of rFVIIa. Its use is recommended when there is a persistent bleeding after the reposition of blood products and when surgical causes of bleeding have been discarded. The cost of the medication should also be considered before its use.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.137 n.6 20092009-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000600016es10.4067/S0034-98872009000600016
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Blood componenit transfusion Factor VII a Postoperative hemorrhage
spellingShingle	Blood componenit transfusion Factor VII a Postoperative hemorrhage López B,Rodrigo Aeschlimann D,Nicolás Carvajal F,Claudia Lema F,Guillermo Uso de factor VII en el control de sangrados perioperatorios: Evidencias actuales
description	Recombinant activated factor VII (rFVIIa) is a new haemostatic drug, originally used for the treatment of patients with hemophilia A and B. At the present time it is used for other bleeding conditions such as the perioperative period. When used prophylactically there is a reduction in the number of bleeding episodes but no changes in the need for blood transfusion or other blood products. The adverse effects are arterial or venous thromboembolic events that are mostly related to the severity of the underlying disease of the patient and the concurrent administration of other haemostatic agents, rather than the use of rFVIIa. Its use is recommended when there is a persistent bleeding after the reposition of blood products and when surgical causes of bleeding have been discarded. The cost of the medication should also be considered before its use.
author	López B,Rodrigo Aeschlimann D,Nicolás Carvajal F,Claudia Lema F,Guillermo
author_facet	López B,Rodrigo Aeschlimann D,Nicolás Carvajal F,Claudia Lema F,Guillermo
author_sort	López B,Rodrigo
title	Uso de factor VII en el control de sangrados perioperatorios: Evidencias actuales
title_short	Uso de factor VII en el control de sangrados perioperatorios: Evidencias actuales
title_full	Uso de factor VII en el control de sangrados perioperatorios: Evidencias actuales
title_fullStr	Uso de factor VII en el control de sangrados perioperatorios: Evidencias actuales
title_full_unstemmed	Uso de factor VII en el control de sangrados perioperatorios: Evidencias actuales
title_sort	uso de factor vii en el control de sangrados perioperatorios: evidencias actuales
publisher	Sociedad Médica de Santiago
publishDate	2009
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000600016
work_keys_str_mv	AT lopezbrodrigo usodefactorviienelcontroldesangradosperioperatoriosevidenciasactuales AT aeschlimanndnicolas usodefactorviienelcontroldesangradosperioperatoriosevidenciasactuales AT carvajalfclaudia usodefactorviienelcontroldesangradosperioperatoriosevidenciasactuales AT lemafguillermo usodefactorviienelcontroldesangradosperioperatoriosevidenciasactuales
_version_	1718436450315272192

Uso de factor VII en el control de sangrados perioperatorios: Evidencias actuales

Ejemplares similares